Abstract
Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.
Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed. Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration. Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.Keywords: Alzheimer's disease, nanoparticles, blood-brain barrier (BBB), central nervous system (CNS), drug delivery, targeted medicine, neurodegeneration.
Current Pharmaceutical Design
Title:Targeted Nanoparticles for the Treatment of Alzheimer's Disease
Volume: 23 Issue: 13
Author(s): Rafael Martín-Rapun*, Laura De Matteis, Alfredo Ambrosone, Sonia Garcia-Embid, Lucia Gutierrez and Jesus M. de la Fuente*
Affiliation:
- Instituto de Nanociencia de Aragón (INA) Universidad de Zaragoza, Edificio I+D, 50018 Zaragoza,Spain
- Instituto de Ciencia de Materiales de Aragón-CSIC/Universidad de Zaragoza, and CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Zaragoza,Spain
Keywords: Alzheimer's disease, nanoparticles, blood-brain barrier (BBB), central nervous system (CNS), drug delivery, targeted medicine, neurodegeneration.
Abstract: Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.
Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed. Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration. Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.Export Options
About this article
Cite this article as:
Martín-Rapun Rafael*, De Matteis Laura, Ambrosone Alfredo, Garcia-Embid Sonia, Gutierrez Lucia and de la Fuente M. Jesus*, Targeted Nanoparticles for the Treatment of Alzheimer's Disease, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666161226151011
DOI https://dx.doi.org/10.2174/1381612822666161226151011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Cholinesterases and Cholinesterase Inhibitors
Current Enzyme Inhibition Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Current Pharmaceutical Design Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Interplay Between Cholesterol and Homocysteine in the Exacerbation of Amyloid-β Toxicity in Human Neuroblastoma Cells
CNS & Neurological Disorders - Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Recent Advances in the Medicinal Chemistry of Sodium Channel Blockers and their Therapeutic Potential
Current Topics in Medicinal Chemistry Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
Current Alzheimer Research Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design